ArticleThe Journal of infectious diseases2023
Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia.
Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance.PLoS biology · 2026Article
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- Immune Responses to Phage Therapy in Humans: A Review.The Journal of infectious diseases · 2026Review
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
- Human bladder organoids model urinary tract infection and bacteriophage therapy.bioRxiv : the preprint server for biology · 2025Article
- Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.International urogynecology journal · 2025Review
- Transcytosis of T4 Bacteriophage Through Intestinal Cells Enhances Its Immune Activation.Viruses · 2025Article
- The Appearance of Antiphage Antibodies in Sera of Patients Treated with Phages.Antibiotics (Basel, Switzerland) · 2025Article
- Multidrug-resistantFrontiers in microbiology · 2025Review
- Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Phage diversity in One Health.Essays in biochemistry · 2024Review
- Translational research priorities for bacteriophage therapeutics.Essays in biochemistry · 2024Review
- Fighting fire with fire: using infectious agents to treat persistent infection.Future microbiology · 2024Review
- Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024Review
- Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model.Nature communications · 2024Article
- Exploring the Bacteriophage Frontier: A Bibliometric Analysis of Clinical Trials Between 1965 and 2024.Cureus · 2024Review
- Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa - A literature review.European journal of microbiology & immunology · 2024Review
- Characterization, antibacterial, and cytotoxic activities of silver nanoparticles using the whole biofilm layer as a macromolecule in biosynthesis.Scientific reports · 2024Article
- Exploring bacteriophage therapy for drug-resistant bacterial infections.Topics in antiviral medicine · 2023Article
- Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Bacteriophage therapy is the use of viruses to kill bacteria for the treatment of antibiotic-resistant infections. Little is known about the human immune response following phage therapy. We report the development of phage-specific CD4 T cells alongside rising phage-specific immunoglobulin G and neutralizing antibodies in response to adjunctive bacteriophage therapy used to treat a multidrug-resistant Pseudomonas aeruginosa pneumonia in a lung transplant recipient. Clinically, treatment was considered a success despite the development phage-specific immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.